#USA #San Diego #Cancer Treatment #Aethlon Medical #Hemopurifier

Aethlon Medical's Second Cohort Update

Aethlon Medical, Inc. (Nasdaq: AEMD), a pioneering company in medical therapeutics, has continuously made strides in its clinical research, particularly in its Australian oncology trial evaluating the efficacy of the Hemopurifier®. This investigational device is designed to treat life-threatening conditions, notably cancer and severe viral infections. Recently, findings from the second cohort in this study revealed promising results that align with earlier observations from the first cohort.

The researchers observed that the second cohort of patients exhibited biological changes in several key areas relevant to tumor dynamics and immune response. These findings reinforce the rationale for the ongoing clinical program and support the continuation of patient enrollment in the final cohort of the study. As the trial progresses, an independent statistical analysis will be conducted to evaluate the full data set.

Key Observations from the Trial

The results from both cohorts signify a trend toward therapeutic efficacy. Notably, some of the impactful observations include:

• - Reduction in Extracellular Vesicles: The second cohort participants demonstrated decreased levels of tumor-derived extracellular vesicles (EVs), platelet-derived EVs, and PD-L1-positive EVs. These markers are significant as they relate directly to tumor growth and immune suppression.
• - Biomarker Changes: Improvements were noted in immune-related laboratory ratios, such as the neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio. These markers have been associated with favorable responses to immunotherapy in previous studies.
• - Increased T Cell Activity: Importantly, there was an increase in total T cells, including CD4 and CD8 T cells, and tumor-specific CD137-positive T cells, all of which play crucial roles in the body's immune response against tumors.

CEO James Frakes expressed optimism regarding these findings, citing the continuity of directional changes across the biomarker landscape as a strong indicator of the Hemopurifier's potential viability as a treatment method. According to Frakes, this consistent performance across both cohorts not only validates initial observations but also enhances the potential to achieve statistically significant results in future analyses.

Clinical Implications and Future Directions

While the Hemopurifier is primarily targeting patients with advanced solid tumors unresponsive to conventional therapies, its design aims to facilitate a breakthrough in cancer care. The device’s ability to reduce immunosuppressive signaling by clearing tumor-related EVs may enhance the body’s capacity to respond to existing cancer therapies, such as PD-1 inhibitors like Keytruda® and Opdivo®.

This trial's focus on early feasibility highlights the emerging role of the Hemopurifier in potentially shaping therapeutic strategies not just in oncology, but possibly extending to infectious diseases and other urgent medical applications. Frakes elaborated on this, alluding to the device’s potential as a multi-faceted platform technology capable of addressing various disease states.

A Note on Study Limitations

Despite these encouraging preliminary results, Aethlon Medical has urged caution. The company notes that these findings are based on raw data from an early-stage feasibility study and that more extensive trials will be necessary to confirm the observed biological changes and their clinical significance. An independent statistician will perform formal analyses after the completion of all study cohorts to ascertain whether the changes imply a dose-response relationship to the Hemopurifier treatment.

Conclusion

As Aethlon Medical moves towards the completion of its clinical trial phases, the focus will remain on strengthening the scientific rationale for the Hemopurifier's use in treating complex conditions like cancer. With enrollment in the third cohort underway and an increasingly robust set of data, there’s a cautious yet palpable excitement surrounding the potential of this novel medical device.

In conclusion, while these early observations are promising, the journey toward validating the clinical implications of the Hemopurifier continues. Stakeholders await the results of the final cohort analysis as potential game-changers in oncology emerge from this innovative approach.

• ---